Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MPL | P40238 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198270 | 0.90 | TGFBR1 (0.42) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5200774 | 0.89 | TGFBR1 (0.39) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5199602 | 0.88 | SCN9A (0.36) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5199511 | 0.87 | TGFBR1 (0.38) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5198993 | 0.86 | TGFBR1 (0.37) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5200017 | 0.86 | TGFBR1 (0.39) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5199208 | 0.85 | TGFBR1 (0.39) | TGFBR1LRRK2PTGS2ALOX5APFEN1 | |
| SCHEMBL5198372 | 0.85 | PTGS2 (0.45) | TGFBR1LRRK2PTGS2PTGS1 | |
| SCHEMBL5199630 | 0.81 | TGFBR1 (0.42) | TGFBR1PTGS2THRB | |
| SCHEMBL5199341 | 0.80 | TGFBR1 (0.44) | TGFBR1PTGS2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885LRRK2 1354/4885PTGS2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.